Last reviewed · How we verify
Tiotropium/Formoterol
Tiotropium is a long-acting anticholinergic that blocks muscarinic receptors to relax airway smooth muscle, while formoterol is a long-acting beta-2 agonist that stimulates bronchodilation, together providing sustained airway opening for chronic obstructive pulmonary disease.
Tiotropium is a long-acting anticholinergic that blocks muscarinic receptors to relax airway smooth muscle, while formoterol is a long-acting beta-2 agonist that stimulates bronchodilation, together providing sustained airway opening for chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy.
At a glance
| Generic name | Tiotropium/Formoterol |
|---|---|
| Also known as | TRITON 18/12 mcg Discair Inhalation Powder |
| Sponsor | Neutec Ar-Ge San ve Tic A.Ş |
| Drug class | Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA) |
| Target | Muscarinic M3 receptor (tiotropium); Beta-2 adrenergic receptor (formoterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Tiotropium acts as a muscarinic M3 receptor antagonist, preventing acetylcholine-induced bronchoconstriction and reducing mucus secretion. Formoterol activates beta-2 adrenergic receptors on airway smooth muscle, increasing cAMP and causing sustained bronchodilation. The combination provides complementary mechanisms for maintenance therapy in COPD and asthma.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Asthma maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Nervousness/anxiety
- Muscle cramps
Key clinical trials
- ANTES B+ Clinical Trial (PHASE4)
- Asthma Research in Children and Adolescents
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
- Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Salvational Intervention for Reducing AECOPD Under Severe Air Pollution (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tiotropium/Formoterol CI brief — competitive landscape report
- Tiotropium/Formoterol updates RSS · CI watch RSS
- Neutec Ar-Ge San ve Tic A.Ş portfolio CI